Pharmala Biotech: CEO Letter To Shareholders | Psychedelic Invest
Over the past 48 hours, a large number of shareholders have reached out to me for my thoughts on the recent FDA Advisory Committee Meeting
Over the past 48 hours, a large number of shareholders have reached out to me for my thoughts on the recent FDA Advisory Committee Meeting
Dessner is an ophthalmologist. Even though I’m probably just average at best when it comes to being environmentally conscious, I still envision myself cruising into
ALX Oncology is cutting two studies of its anti-CD47 drug evorpacept after it failed to show substantial efficacy. In its second-quarter report Thursday afternoon, ALX